Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study-Reference-Cited by-同舟云学术

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

Published:2024-04-03 Issue: Volume: Page:
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Pérez-Lamas Lucía,de Paz Arias Raquel,Díaz Rosa Mª Ayala,Montero Luis Felipe Casado,Payer Ángel Ramírez,Sierra Magdalena,Marín Francisca Ferrer,López Raúl Pérez,Cirici Blanca Xicoy,Steegmann Juan Luis,Gómez Casares María Teresa,Martínez-López Joaquín,García-Gutiérrez Valentín

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05662-7.pdf

Reference50 articles.

1. Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044–1054. https://doi.org/10.1038/leu.2016.5

2. Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-Year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic myeloid leukemia patients trial. J Clin Oncol 34:2333–2340. https://doi.org/10.1200/JCO.2015.64.8899

3. Brümmendorf TH, Cortes JE, Milojkovic D et al (2022) Bosutinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia 36:1825–1833. https://doi.org/10.1038/s41375-022-01589-y

4. Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747–757. https://doi.org/10.1016/S1470-2045(18)30192-X

5. Campiotti L, Suter MB, Guasti L et al (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 77:48–56. https://doi.org/10.1016/j.ejca.2017.02.028

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity;Toxicology Letters;2024-10